EQUIPThe Verge · 1d ago
Claude did not invent scorpion antivenom
Executive Brief
The 30-second read
An investment firm partnered with Anthropic to test an unreleased AI model’s capacity for automated drug development. Results indicate that while the system identified potential biological starting points, it failed to produce a viable scorpion antivenom.
- 01Citrini Research tested an unreleased version of Claude for specialized pharmaceutical discovery capabilities
- 02Independent experts confirmed the AI failed to generate a functional drug candidate during the trial
- 03The experiment highlights current limitations in utilizing LLMs for end-to-end biochemical engineering
- 04Research outputs provided promising initial data but lacked the complexity required for medical application
Go deeper · Equip playbook
Business Travel Management 2026: Program Blueprint →AI-generated summary · Verify at source
An investment research firm wanted to prove AI could revolutionize drug development. So they teamed up with Anthropic to see whether an unreleased version of Claude could make scorpion antivenom. It couldn't. It came up with some promising starting points, but nothing close to an actual drug, experts tell The Verge. Citrini Research, the firm […]